| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/18/2003 | US6521262 Solid instant-release forms of administration and process for producing the same |
| 02/18/2003 | US6521261 Pharmaceutical excipient having improved compressibility |
| 02/18/2003 | US6521259 Controlled release material comprising polyanhydrides, copolymers of lactic acid and glycolic acid, polylactic acid, polyglycolic acid, polyesters, polyorthoesters, proteins, polysaccharides; ouabain, digoxin |
| 02/18/2003 | US6521256 Stabilized pharmaceutical composition |
| 02/18/2003 | US6521253 Low molecular weight peptide thrombin inhibitor having pH dependent solubility and a combination of microcrystalline cellulose and sodium starch glycollate |
| 02/18/2003 | US6521252 Comprises one or several disulphide bonds; cationic lipid type |
| 02/18/2003 | US6521250 Transdermal therapeutic system containing estradiol |
| 02/18/2003 | US6521248 Cavitation; reduced pressure; oxygenated water |
| 02/18/2003 | US6521243 Ionic chitosan -iodine complexes: antiseptic hydrogels and wound healing promoters |
| 02/18/2003 | US6521242 Method for sequestration of nasal secretion skin irritants with facial tissue |
| 02/18/2003 | US6521241 That can bind a cytokine; clay, silica, titanium dioxide, and combinations thereof |
| 02/18/2003 | US6521240 That can bind a cytokine; clay, silica, titanium dioxide, and combinations thereof |
| 02/18/2003 | US6521234 NL3 TIE ligand homologue |
| 02/18/2003 | US6521223 Reacting anionic polymers with divinyl sulfone, neutralizing, then precipitating solids, then hydrating to form water insoluble biocompatible mucopolysaccharides having storage stability used as antiscarring wound healing agents |
| 02/18/2003 | US6521213 Administering mixtures of lipids, surfactants, dispersants, propellants and drugs such as antibiotics, bactericides, viricides and fungicides to the ears; protective coatings that reduce surface tension of the air/liquid interfaces |
| 02/18/2003 | CA2351004C Formulation |
| 02/18/2003 | CA2230137C Topical composition comprising a hydrophilic polyester sulfone gelling agent |
| 02/18/2003 | CA2085750C Osteoinductive pharmaceutical formulations |
| 02/17/2003 | CA2398112A1 2-(3,4-dihydroxyphenyl)ethyl-substituted carbonic acid derivatives and their use |
| 02/17/2003 | CA2356390A1 Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof |
| 02/13/2003 | WO2003012111A2 Conjugates for the modulation of immune responses |
| 02/13/2003 | WO2003012072A2 Monoclonal antibodies to activated erbb family members and methods of use thereof |
| 02/13/2003 | WO2003012039A2 Targeting nucleic acids to a cellular nucleus |
| 02/13/2003 | WO2003011912A1 Chitosan preparation |
| 02/13/2003 | WO2003011909A1 Binding agents with differential activity |
| 02/13/2003 | WO2003011879A1 Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same |
| 02/13/2003 | WO2003011874A1 Compounds for use as surfactants |
| 02/13/2003 | WO2003011421A2 Emulsifier mixture |
| 02/13/2003 | WO2003011396A1 Tetrahydroindolone and purine derivatives linked to arylpiperazines |
| 02/13/2003 | WO2003011345A1 Lipid constructs as therapeutic and imaging agents |
| 02/13/2003 | WO2003011342A2 Targeted polymeric delivery systems |
| 02/13/2003 | WO2003011341A1 Solid composition containing bacillus-type non-pathogenic bacterial spores |
| 02/13/2003 | WO2003011340A1 Medicament formulation for topical application in the therapy and prophylaxis of hyperhidrosis |
| 02/13/2003 | WO2003011339A1 Composition for epigallocatechin gallate |
| 02/13/2003 | WO2003011334A1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv |
| 02/13/2003 | WO2003011316A1 Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome |
| 02/13/2003 | WO2003011306A1 Sucralose formulations to mask unpleasant tastes |
| 02/13/2003 | WO2003011303A1 Dermal therapy using phosphate derivatives of electron transfer agents |
| 02/13/2003 | WO2003011283A1 Pharmaceutical compositions of amlodipine and atorvastatin |
| 02/13/2003 | WO2003011278A1 Crystalline composition containing escitalopram |
| 02/13/2003 | WO2003011268A1 (+)-cycloolivil as antioxidant obtained from stereospermum personatum |
| 02/13/2003 | WO2003011266A2 Azalide antibiotic compositions |
| 02/13/2003 | WO2003011255A1 Gastric retention controlled drug delivery system |
| 02/13/2003 | WO2003011253A1 Synergistic filler composition |
| 02/13/2003 | WO2003011252A1 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
| 02/13/2003 | WO2003011251A1 Pulmonary formulation |
| 02/13/2003 | WO2003011249A2 Ophthalmic composition containing n-acetylcysteine for the treat ment of dry-eye syndrome |
| 02/13/2003 | WO2003011248A1 Flat, oral dosage form comprising particles containing active ingredients |
| 02/13/2003 | WO2003011247A2 Support matrix comprising particles loaded with active ingredient for application on the skin or mucous membrane |
| 02/13/2003 | WO2003011239A2 Sunscreen composition |
| 02/13/2003 | WO2003011230A2 Modified reoviral therapy |
| 02/13/2003 | WO2003011227A2 Taste masking composition |
| 02/13/2003 | WO2003011226A2 Products and drug delivery vehicles |
| 02/13/2003 | WO2003011224A2 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| 02/13/2003 | WO2003011212A2 Biodegradable polyhydric alcohol esters |
| 02/13/2003 | WO2003011211A2 Peg-modified uricase |
| 02/13/2003 | WO2003011207A2 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine |
| 02/13/2003 | WO2003011115A2 Peptide-based multimeric targeted contrast agents |
| 02/13/2003 | WO2003011051A1 Process for preparing concentrate thickener compositions |
| 02/13/2003 | WO2003011008A2 Therapeutic delivery compositions and methods of use thereof |
| 02/13/2003 | WO2002096948A9 Engineered tetravalent antibodies and methods of use |
| 02/13/2003 | WO2002096457A3 Stable liquid formulations of antibodies |
| 02/13/2003 | WO2002087546A3 Method for manufacturing a low dose pharmaceutical composition |
| 02/13/2003 | WO2002083079A3 Aerosol compositions containing formoterol for delivery to the lungs via nebulization |
| 02/13/2003 | WO2002078638A3 Morpholino imaging and therapy |
| 02/13/2003 | WO2002072011A3 Stabilized therapeutic and imaging agents |
| 02/13/2003 | WO2002069232A3 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| 02/13/2003 | WO2002067761A3 Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque |
| 02/13/2003 | WO2002066067A3 Albumin-based drug delivery system and antimicrobial peptides |
| 02/13/2003 | WO2002062810A3 Linkable sialyl lewis x analogs |
| 02/13/2003 | WO2002060454B1 Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders |
| 02/13/2003 | WO2002059261A3 Inhibition of restenosis using a dna-coated stent |
| 02/13/2003 | WO2002049667A3 Vaccine for treating nicotine addiction |
| 02/13/2003 | WO2002043765A9 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| 02/13/2003 | WO2002040056A8 Carrageenan viscoelastics for ocular surgery |
| 02/13/2003 | WO2002038129A3 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 02/13/2003 | WO2002028382A9 Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals |
| 02/13/2003 | WO2002013791A3 Steroid hormones as transfer agents |
| 02/13/2003 | US20030032995 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 02/13/2003 | US20030032909 Plaster containing an active agent |
| 02/13/2003 | US20030032677 Contains peroxidic species or reaction products resulting from oxidation of geraniol via ozone; for treating horses infected with Sarcocystis protozoal infections |
| 02/13/2003 | US20030032659 Stabilization of retinoid compounds |
| 02/13/2003 | US20030032640 Novel composition |
| 02/13/2003 | US20030032639 Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using surfactants and amino acids |
| 02/13/2003 | US20030032632 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| 02/13/2003 | US20030032610 Administering one or more oligonucleotides which share at least 50% nucleotide sequence identity with (TTAGGG)n or oligonucleotides which share at least 50% nucleotide sequence identity with the human telomere overhang repeat. |
| 02/13/2003 | US20030032605 EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections |
| 02/13/2003 | US20030032600 Taste masked liquid pharmaceutical compositions |
| 02/13/2003 | US20030032597 Targeting nucleic acids to a cellular nucleus |
| 02/13/2003 | US20030032594 Intracellular delivery of biological effectors |
| 02/13/2003 | US20030032593 Transporters comprising spaced arginine moieties |
| 02/13/2003 | US20030032588 Glucagon antagonists |
| 02/13/2003 | US20030032584 Inhibiting abnormal cellular proliferation in a mammal; and a method of inhibiting replication of a virus in a mammal. |
| 02/13/2003 | US20030031716 Biocompatible polymer and particles of metal cation-stabilized interferon dispersed within the polymer |
| 02/13/2003 | US20030031715 Increasing the water solubility of poorly soluble drugs such as paclitaxel, griseofulvin, progesterone, or tamoxifen using hydrotropic agent monomers, polymers, or hydrogels, which contain at least one hydrophobic moiety |
| 02/13/2003 | US20030031713 Extended release oral dosage composition |
| 02/13/2003 | US20030031711 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| 02/13/2003 | US20030031708 Comprising vinylpyrrolidone-vinyl acetate copolymer and microcrystalline cellulose; for making pharmaceutical tablets of sufficient tablet hardness at low compression force and low friability to preclude damage on processing |
| 02/13/2003 | US20030031706 Carotenoid formulations, comprising a mixture of beta-carotene, lycopene and lutein |
| 02/13/2003 | US20030031704 Liposome composition for delivery of nucleic acid |